AU2021371040C1 - Interleukin-18 variants and methods of use - Google Patents

Interleukin-18 variants and methods of use Download PDF

Info

Publication number
AU2021371040C1
AU2021371040C1 AU2021371040A AU2021371040A AU2021371040C1 AU 2021371040 C1 AU2021371040 C1 AU 2021371040C1 AU 2021371040 A AU2021371040 A AU 2021371040A AU 2021371040 A AU2021371040 A AU 2021371040A AU 2021371040 C1 AU2021371040 C1 AU 2021371040C1
Authority
AU
Australia
Prior art keywords
polypeptide
seq
variant
stabilized
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021371040A
Other languages
English (en)
Other versions
AU2021371040B2 (en
AU2021371040A1 (en
Inventor
Tom Boone
Aaron RING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Simcha Il 18 Inc
Yale University
Original Assignee
Simcha Il 18 Inc
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simcha Il 18 Inc, Yale University filed Critical Simcha Il 18 Inc
Publication of AU2021371040A1 publication Critical patent/AU2021371040A1/en
Publication of AU2021371040B2 publication Critical patent/AU2021371040B2/en
Priority to AU2025203386A priority Critical patent/AU2025203386A1/en
Application granted granted Critical
Publication of AU2021371040C1 publication Critical patent/AU2021371040C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021371040A 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use Active AU2021371040C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203386A AU2025203386A1 (en) 2020-11-02 2025-05-12 Interleukin-18 variants and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108794P 2020-11-02 2020-11-02
US63/108,794 2020-11-02
PCT/US2021/057741 WO2022094473A1 (en) 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203386A Division AU2025203386A1 (en) 2020-11-02 2025-05-12 Interleukin-18 variants and methods of use

Publications (3)

Publication Number Publication Date
AU2021371040A1 AU2021371040A1 (en) 2023-06-22
AU2021371040B2 AU2021371040B2 (en) 2025-02-13
AU2021371040C1 true AU2021371040C1 (en) 2025-05-29

Family

ID=81384408

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021371040A Active AU2021371040C1 (en) 2020-11-02 2021-11-02 Interleukin-18 variants and methods of use
AU2025203386A Pending AU2025203386A1 (en) 2020-11-02 2025-05-12 Interleukin-18 variants and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203386A Pending AU2025203386A1 (en) 2020-11-02 2025-05-12 Interleukin-18 variants and methods of use

Country Status (14)

Country Link
US (3) US11850276B2 (https=)
EP (1) EP4236990A4 (https=)
JP (1) JP2023550545A (https=)
KR (1) KR20230117120A (https=)
CN (1) CN116723851A (https=)
AR (1) AR123978A1 (https=)
AU (2) AU2021371040C1 (https=)
CA (1) CA3197145A1 (https=)
GB (1) GB2617483B (https=)
IL (1) IL302517A (https=)
MX (1) MX2023005068A (https=)
NZ (1) NZ800435A (https=)
TW (1) TW202233657A (https=)
WO (1) WO2022094473A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
US20230146665A1 (en) 2021-07-27 2023-05-11 Xencor, Inc. Il-18-fc fusion proteins
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
US20260092093A1 (en) * 2022-09-06 2026-04-02 TJ Biopharma (Shanghai) Co., Ltd. Il-18 variant polypeptides
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
AU2024212675A1 (en) * 2023-01-24 2025-07-31 Simcha IL-18, Inc. Methods and compositions for combination therapy
WO2024259270A2 (en) * 2023-06-16 2024-12-19 Simcha IL-18, Inc. Administration of engineered interleukin-18 therapeutics
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025041097A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
CN120189493A (zh) * 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091517A2 (en) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US20190070262A1 (en) * 2017-09-06 2019-03-07 Yale University Interleukin-18 variants and methods of use
WO2022038417A2 (en) * 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
EP0816499A3 (en) 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP2007143555A (ja) * 1996-11-29 2007-06-14 Hayashibara Biochem Lab Inc ポリペプチド
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
CN1457258A (zh) 2000-06-02 2003-11-19 史密丝克莱恩比彻姆公司 用il－18和il－18组合物治疗病毒性疾病的方法
WO2002101049A2 (en) 2001-03-08 2002-12-19 Ares Trading S.A. Interleukin-18 mutants, their production and use
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
HUE060304T2 (hu) * 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
WO2017102010A1 (en) 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP2020143000A (ja) * 2019-03-04 2020-09-10 大陽日酸株式会社 融合タンパク質及びその製造方法、目的タンパク質の製造方法
US12029778B2 (en) * 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091517A2 (en) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US20190070262A1 (en) * 2017-09-06 2019-03-07 Yale University Interleukin-18 variants and methods of use
WO2022038417A2 (en) * 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yamamoto, Y. et al., "Generation of highly stable IL-18 based on a ligand–receptor complex structure," Biochemical and biophysical research communications, 2004, 317(1), pp.181-186. *

Also Published As

Publication number Publication date
MX2023005068A (es) 2023-07-14
US11850276B2 (en) 2023-12-26
US20240066100A1 (en) 2024-02-29
AU2021371040B2 (en) 2025-02-13
AR123978A1 (es) 2023-02-01
US20230277625A1 (en) 2023-09-07
EP4236990A4 (en) 2025-03-19
GB2617483B (en) 2025-03-12
EP4236990A1 (en) 2023-09-06
AU2025203386A1 (en) 2025-06-05
NZ800435A (en) 2025-12-19
TW202233657A (zh) 2022-09-01
CA3197145A1 (en) 2022-05-05
CN116723851A (zh) 2023-09-08
US12564621B2 (en) 2026-03-03
GB202308183D0 (en) 2023-07-19
AU2021371040A1 (en) 2023-06-22
IL302517A (en) 2023-07-01
US12582701B2 (en) 2026-03-24
GB2617483A (en) 2023-10-11
JP2023550545A (ja) 2023-12-01
US20240075104A1 (en) 2024-03-07
KR20230117120A (ko) 2023-08-07
WO2022094473A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
AU2021371040C1 (en) Interleukin-18 variants and methods of use
US12403180B2 (en) Interleukin-18 variants and methods of use
US20240374679A1 (en) Interleukin-18 mimics and methods of use
EP4556486A1 (en) Trispecific antibody and use thereof
CA3229251A1 (en) Interleukin-12 variants and methods of use
RU2797536C2 (ru) Варианты интерлейкина-18 и способы их применения
HK40100300A (zh) 白介素-18变体和使用方法
HK40081595A (zh) 三特异性抗体及其用途

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 FEB 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 03 FEB 2025

FGA Letters patent sealed or granted (standard patent)